Log In
BCIQ
Print this Print this
 

Xenopax, biosimilar daclizumab

  Manage Alerts
Collapse Summary General Information
Company 3SBio Inc.
DescriptionBiosimilar of daclizumab, a humanized mAb against interleukin-2 (IL-2) receptor alpha chain (CD25)
Molecular Target Interleukin-2 (IL-2) receptor alpha chain (CD25)
Mechanism of ActionAntibody; Biosimilar
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentMarketed
Standard IndicationRenal transplant
Indication DetailsPrevent renal transplant rejection
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

2

$219.4M

$219.4M

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

11/20/2015

$219.4M

$219.4M

0

12/23/2014

Undisclosed

Undisclosed

Undisclosed

Get a free BioCentury trial today